STONE Clinical Laboratories offers an advanced molecular testing solution for common infections using PCR technology. This advanced technology accurately and definitively identifies the exact causative pathogen by its DNA/RNA. By identifying the pathogen(s), clinicians can treat patients quicker with the appropriate diagnosis.
Stone Clinical Laboratories LLC, a CAP accredited and CLIA-certified laboratory in New Orleans, Louisiana, is excited to announce that beginning May 4th our lab has expanded its COVID-19 testing capacity to 5,000 tests per day since it first began accepting specimens for COVID-19 testing on March 19, 2020. In addition, Stone can now announce that it is able to perform up to 9,000 COVID-19 antibody tests per day.
“Stone feels privileged to have the opportunity to rise to this challenge after introducing COVID-19 testing last month,” said Stone Clinical Laboratories’ founder and CEO, Christopher Ridgeway. “I am proud of the team we have here at Stone, first using their expertise and dedication to perform COVID-19 testing, and now continuing to apply that same diligence and expertise so that we can process even more tests for the community and introduce antibody testing. I can speak for all of us here at Stone that we are honored to play a part in the testing process for those effected by this national health crisis.” Learn More
Molecular Testing by PCR – the better solution
UTIs are among the most prevalent community acquired and hospital acquired infections, affecting almost 50% of the population at least once in their lifetime, and account for considerable amounts of morbidity and healthcare expenditure in the US, with an estimated annual cost of $3.5 billion.(1)
Traditional urine cultures missed 67% of uropathogens overall and 50% in the group with severe symptoms according to research published in the Journal of Clinical Microbiology; May 2016 T. Price et al.
UTIs are among the most prevalent community acquired and hospital acquired infections, affecting almost 50% of the population at least once in their lifetime, and account for considerable amounts of morbidity and healthcare expenditure in the US, with an estimated annual cost of $3.5 billion.(1)
Traditional urine cultures missed 67% of uropathogens overall and 50% in the group with severe symptoms according to research published in the Journal of Clinical Microbiology; May 2016 T. Price et al.
Sexually transmitted diseases (STDs) are major causes of acute illness and infertility worldwide. The World Health Organization (WHO) estimates 499 million new cases of STDs occur annually worldwide in adults aged 15-49 years. The performance of nucleic acid amplification tests (PCR) with respect to overall sensitivity, specificity, and ease of specimen transport is better than that of any of the other tests available for the diagnosis of chlamydia and gonorrhea infections (1)
STD Product sheet
Molecular Requisition
BV Sample Report
HVP Sample Report
COVID-19 Testing is now available! View the RPP and COVID-19 Requisition
A variety of viruses and some bacteria (pathogens) can cause infections of the respiratory tract. RPP testing through naspharyngeal swabs provides simultaneous qualitative detection and identification of multiple respiratory viruses and bacteria from patients whom are suspected for respiratory infections. Respiratory infections are increasing each year. According to the CDC the number of cases of influenza during 2018 was the highest since 2009.
Onychomycosis, the most common nail disease in the US, is a fungal infection of the fingernails or toenails that may involve any component of the nail unit, including the matrix, bed or plate. Treatment of onychomycosis is very expensive and requires long-term therapy, therefore, a proper diagnosis is needed.
Traditional cultures fail to grow more than 85% of organisms identified in chronic wounds. Cultures also have limitations which render them almost irrelevant for the diagnosis of polymicrobial clinical and biofilm infections.